4/A: Artivion VP Matthew Getz Amends SEC Filing to Correct Share Sale Reporting

Matthew Getz, VP of Human Resources at Artivion, Inc., files an amended SEC Form 4/A to correct the number of shares sold to cover tax withholding obligations.

Summary

• Matthew Getz, VP of Human Resources at Artivion, Inc., filed an amended SEC Form 4/A on March 14, 2024, to correct errors in a previous filing from February 28, 2024.
• The amendment addresses inaccuracies in the number of shares sold on February 26, 2024, to cover tax withholding obligations related to the vesting of performance stock units.
• The original filing incorrectly reported the sale of 1,185 shares and 1,128 shares in two separate transactions, while the corrected numbers are 1,168 and 1,112 shares, respectively.
• As a result of these corrections, the number of shares reported as beneficially owned has been adjusted upwards.
• Getz acquired 3,366 and 7,412 shares of common stock on February 23, 2024, related to performance stock units vesting.
• Following the reported transactions, Getz beneficially owns 46,440 shares of Artivion, Inc. common stock.

Sentiment

Score: 7

Explanation: The document is a routine correction of an administrative error in an SEC filing. While the error itself is slightly negative, the correction is positive. The vesting of performance stock units is generally a positive sign, aligning management interests with shareholders.

Positives

• The amendment clarifies previous reporting errors, providing a more accurate view of Getz's share ownership.
• The filing indicates the vesting of performance stock units, aligning Getz's interests with the company's performance.

Negatives

• The need for an amendment suggests an initial administrative oversight in reporting share sales.

Risks

• Inaccurate reporting, even if corrected, can temporarily create uncertainty for investors.

Future Outlook

Future vesting of performance stock units is scheduled for February 22, 2025 (25%) and February 22, 2026 (25%), contingent upon continued employment.

Industry Context

This filing is a routine disclosure related to executive compensation and share ownership, common in publicly traded companies. It doesn't necessarily reflect broader industry trends but provides insight into individual executive holdings and equity-based compensation structures.

Comparison to Industry Standards

• Executive compensation packages including performance stock units are common across the medical device industry.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize equity-based compensation to align executive interests with shareholder value.
• The vesting schedules and performance metrics associated with these units vary by company and individual circumstances.

Stakeholder Impact

• Shareholders benefit from accurate reporting of executive share ownership.
• The vesting of performance stock units incentivizes the executive to contribute to the company's success.

Key Dates